This site is part of the Informa Connect Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067.

BIO-Europe Spring
March 18–20, 2024 | Barcelona, SpainMarch 26–27, 2024 | Digital Partnering

Energenesis Biomedical Co., Ltd.


Energenesis Biomedical is founded in 2012 and granted the qualification of biomedicine company in Taiwan. Energenesis Biomedical employs unique ENERGI medicine development platform, activating AMP activated protein kinase (AMPK) and thereby enhancing cellular energy, for the cure of diseases. Our mission is to develop new drugs with the ENERGI platform, with our features in elevating the quality of life and addressing unmet medical needs through novel approaches. New medicines being developed by the company which has entered the stage of clinical trials include ENERGI-F703, gels for treating diabetes foot ulcer, which has embarked on a phase III trial in US/TW, and ENERGI-F701, a phase II completed project for female hair pattern loss. Backed by a solid R&D team, Energenesis Biomedical has entered into cooperation with domestic and overseas academic and research bodies, sustaining research dynamism and resulting in an abundant product lineup. During the development process of pharmaceuticals, the company has been in active talks with foreign pharmaceutical firms for technology transfer, in order to maximize the intellectual-property benefits of new medicines. Despite its young team, Energenesis Biomedical has a strong sense of mission, taking advantage of our strong power in execution and judgment in a relentless quest for constant improvement of its expertise and technology, so as to maximize the curing effect of new medicines.